Exploring SARS-CoV-2 and Plasmodium falciparum coinfection in human erythrocytes

Front Immunol. 2023 Mar 13:14:1120298. doi: 10.3389/fimmu.2023.1120298. eCollection 2023.

Abstract

The co-occurrence and the similarities between malaria and COVID-19 diseases raise the question of whether SARS-CoV-2 is capable of infecting red blood cells and, if so, whether these cells represent a competent niche for the virus. In this study, we first tested whether CD147 functions as an alternative receptor of SARS-CoV-2 to infect host cells. Our results show that transient expression of ACE2 but not CD147 in HEK293T allows SARS-CoV-2 pseudoviruses entry and infection. Secondly, using a SARS-CoV-2 wild type virus isolate we tested whether the new coronavirus could bind and enter erythrocytes. Here, we report that 10,94% of red blood cells had SARS-CoV-2 bound to the membrane or inside the cell. Finally, we hypothesized that the presence of the malaria parasite, Plasmodium falciparum, could make erythrocytes more vulnerable to SARS-CoV-2 infection due to red blood cell membrane remodelling. However, we found a low coinfection rate (9,13%), suggesting that P. falciparum would not facilitate the entry of SARS-CoV-2 virus into malaria-infected erythrocytes. Besides, the presence of SARS-CoV-2 in a P. falciparum blood culture did not affect the survival or growth rate of the malaria parasite. Our results are significant because they do not support the role of CD147 in SARS-CoV-2 infection, and indicate, that mature erythrocytes would not be an important reservoir for the virus in our body, although they can be transiently infected.

Keywords: ACE2; CD147; COVID-19; malaria; novel coronavirus; red blood cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19*
  • Coinfection*
  • Erythrocytes
  • HEK293 Cells
  • Humans
  • Malaria, Falciparum* / parasitology
  • Plasmodium falciparum
  • SARS-CoV-2

Grants and funding

This project received funding from the Spanish National Research Council through the grant 202020E159 within the PTI Salud Global initiative and Spanish Ministry of Science and Innovation (grant: PID2019-111109RB-I00).